Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic.
Each year, approximately five million people die worldwide from putatively vaccine-preventable mucosally transmitted diseases. With respect to mass vaccination campaigns, one strategy to cope with this formidable challenge is aerosol vaccine delivery, which offers potential safety, logistical, and cost-saving advantages over traditional vaccination routes. Additionally, aerosol vaccination may elicit pivotal mucosal immune responses that could contain or eliminate mucosally transmitted pathogens in a preventative or therapeutic vaccine context. In this current preclinical non-human primate investigation, we demonstrate the feasibility of aerosol vaccination with the recombinant poxvirus-based vaccine vectors NYVAC and MVA. Real-time in vivo scintigraphy experiments with radiolabeled, aerosol-administered NYVAC-C (Clade C, HIV-1 vaccine) and MVA-HPV vaccines revealed consistent mucosal delivery to the respiratory tract. Furthermore, aerosol delivery of the vaccines was safe, inducing no vaccine-associated pathology, in particular in the brain and lungs, and was immunogenic. Administration of a DNA-C/NYVAC-C prime/boost regime resulted in both systemic and anal-genital HIV-specific immune responses that were still detectable 5 months after immunization. Thus, aerosol vaccination with NYVAC and MVA vectored vaccines constitutes a tool for large-scale vaccine efforts against mucosally transmitted pathogens.
Corbett
Max
M
EuroVacc Foundation, Institut Swisse de Recherche Expérimentale sur la Cancer, CH-1066, Epalinges, Switzerland.
Bogers
Willy M
WM
Heeney
Jonathan L
JL
Gerber
Stefan
S
Genin
Christian
C
Didierlaurent
Arnaud
A
Oostermeijer
Herman
H
Dubbes
Rob
R
Braskamp
Gerco
G
Lerondel
Stéphanie
S
Gomez
Carmen E
CE
Esteban
Mariano
M
Wagner
Ralf
R
Kondova
Ivanella
I
Mooij
Petra
P
Balla-Jhagjhoorsingh
Sunita
S
Beenhakker
Niels
N
Koopman
Gerrit
G
van der Burg
Sjoerd
S
Kraehenbuhl
Jean-Pierre
JP
Le Pape
Alain
A
D000336:Aerosols; D000818:Animals; D005822:Genetic Vectors; D008253:Macaca mulatta; D014018:Tissue Distribution; D014612:Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000235:genetics / Q000276:immunology / Q000493:pharmacokinetics
D000336:Aerosols; D014612:Vaccines